E.g., 09/24/2021
E.g., 09/24/2021
Title Category Credit Event Date Price
AUA Live en español (2020) $0.00 ¡La AUA le entrega una experiencia de educación virtual mostrando lo mejor de la AUA!En junio, más de 4,000 participantes de todo el mundo asistieron a AUA Live, un evento de transmisión en vivo de dos días de duración que contó con más de 35 horas de programación educativa selecta, incluida una conferencia magistral del Dr.
Addressing Disparities in Prostate Cancer Care Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 1 (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Podcast: Part 2 (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
AUA Guidelines on Advanced/Metastatic/Castration Resistant Prostate Cancer Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 This course will review the important and newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive (HSPC) and Castration-Resistant Prostate Cancer (CRPC). This includes a thorough discussion of new trials and approval of agents directed at the androgen axis for treatment of M1 HSPC and non-metastatic MO CRPC. Faculty will highlight the management of patients with advanced prostate cancer, including mHSPC, nmCRPC, and CRPC, and how therapeutic options have been incorporated into evidence-based guidelines.
AUA Live (2020) $299.00 June 27 – 28, 2020The AUA brings you a virtual education experience featuring the best of AUA! This program will include two days of virtual programming across three different channels, providing more than 24 hours of education. Explore the program below.
Case-Based Discussion: BCR and mHSPC & M0 CRPC Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
Case-Based Discussion: Early M1 CRPC Management & Advanced M1 CRPC Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
Case-Based Discussion: Role of Genetic Testing in Advanced M1 CRPC & M1 CRPC Post-Docataxel Chemotherapy and End-of-Life Care Podcast (2020)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). 
CPS Castration-Resistant Prostate Cancer Amendment (2018)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The goal of this Guideline is  to provide a rational basis for treatment of patients with CRPC, based on currently available published data.
Genetic Testing and Personalized Medicine in Prostate Cancer Podcast (2020)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease, & Castration Resistant Prostate...
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g.
Incorporating Genomic Testing For Prostate Cancer into Your Practice Webcast (2021)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There are multiple genomic tests currently available for men with localized prostate cancer. The outcomes of these tests may lead to different treatment decisions (active surveillance, surgery, radiation, etc) or impact the frequency of monitoring. The availability and marketing of genomic testing has outpaced a reflective, evidence based medicine approach to using these tests.
Life Long Learning Knowledge Assessment Course: Multi-Parametric Ultrasound in the Diagnosis of Prostate Cancer Webcast 011IC (2018)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$99.00 Transrectal ultrasound is critical to biopsy guidance for the diagnosis of prostate cancer. However, ultrasound has the ability to improve diagnostic accuracy and may perform as well as multi-parametric MRI in identifying suspicious lesions.
Live from AUA2021: Highlights in Advanced Prostate Cancer (2021)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 Live from AUA2021: Highlights in Advanced Prostate Cancer is a panel discussion filmed LIVE at the 2021 AUA Annual Meeting!

Pages